Drug data last refreshed 3h ago · AI intelligence enriched 3w ago
NAQUA (trichlormethiazide) is an oral thiazide diuretic approved in 1960 for the treatment of hypertension and edema. It works by inhibiting sodium and chloride reabsorption in the distal convoluted tubule, reducing blood volume and vascular resistance. The drug is indicated for patients with hypertension and fluid retention disorders.
As a legacy diuretic approaching loss of exclusivity, the NAQUA team is likely focused on cost management and defending market share against generic competition rather than expansion.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
With 604 linked jobs, NAQUA offers career opportunities primarily in commercial management, manufacturing optimization, and clinical operations support. Working on a LOE-stage product develops expertise in defending market share, managing generic competition, cost-per-unit optimization, and legacy portfolio stewardship—valuable skills for pharma professionals managing mature or transitioning products.
Worked on NAQUA at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
604 open roles linked to this drug